Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Bristol-Myers Squibb (BMY)

NYSE: BMY · Pharmaceuticals · Princeton, NJ

Our rating: Positive

Positive reaffirmed at $62.48, moderate conviction, October 30, 2026.

Breaks if: The positive view breaks if full-year revenue falls more than 3% in the next annual filing — a move that would signal the growth portfolio is failing to replace lost volume and that flat revenues were a high-water mark rather than a trough. It also breaks if trailing twelve-month free cash flow drops below $10B within the next four quarters, which would collapse the FCF yield anchoring the call. Either condition, confirmed within twelve months of this publication, would shift the view negative.

Key figures

Market value$120.2B
Revenue, last 12 months$50.0B
Net income, last 12 months$9.2B
Free cash flow, last 12 months$9.3B
Price to earnings13.0×
Free cash flow yield7.7%
Dividend yield4.3%
Operating marginn/a
Return on equity44.1%
Beta to the S&P 5000.23
Volatility, annualized29.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$13.1B6.9%$1.05$3.8B
June 30, 2026$13.0B5.7%$1.62$3.1B
March 31, 2026$11.5B2.6%$1.31$757M
December 31, 2025$12.5B1.3%$0.53$1.6B
September 30, 2025$12.2B2.8%$1.08$6.0B
June 30, 2025$12.3B0.6%$0.64$3.6B
March 31, 2025$11.2B−5.6%$1.20$1.7B
December 31, 2024$12.3B7.5%$0.04$4.1B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

16 ledger entries and 33 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.